485 results about "Viral replication" patented technology

The invention provides a construction method and application of a high-efficiency expression system based on a Seali forest virus replicon. The method comprises the following steps: constructing a saRNA system for expressing a reporter gene; constructing to obtain replicase providing plasmids in the taRNA system; constructing to obtain an antigen providing plasmid in the taRNA system; the method comprises the following steps: respectively linearizing pSFV-CMV-T7-X, pSFV-CMV-T7-TR-X and pSFV-CMV-T7-replicase, and then carrying out in vitro transcription to prepare mRNA (Messenger Ribonucleic Acid); transfecting the prepared mRNA into a host eukaryotic cell for expression according to a certain proportion to obtain an antigen protein; and detecting the antigen protein to evaluate the expression efficiency of the saRNA and taRNA system based on the SFV replicon. According to the self-amplification DNA and RNA vaccine based on the virus replicon, the development period can be shortened, and the vaccine antigen can be expressed at a high level.

Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.

The invention relates to a bioengineering technology, and aims to provide a polypeptide for enhancing porcine epidemic diarrhea virus replication and application thereof. The polypeptide is a transmembrane polypeptide targeting a PEDV replication stage, and 58th arginine in a nucleocapsid N protein sequence of PEDV is used as a target; the polypeptide is named as R58-WT polypeptide, and the amino acid sequence of the polypeptide is as shown in SEQ ID NO: 1. According to the invention, a key site influencing virus replication in an N-terminal region of PEDV N protein is used as a new target spot, the polypeptide has a very significant promotion effect in PEDV infection model verification experiments of IPEC-J2, Vero and ST cells, and the problems of weak low-generation virulence, poor cell adaptability, difficulty in passage and the like in the process of rescuing PEDV low virulent strains can be perfectly solved.

The invention relates to a bioengineering technology, and aims to provide a polypeptide for inhibiting replication of a porcine epidemic diarrhea virus and application of the polypeptide. The polypeptide is a transmembrane polypeptide targeting a PEDV replication stage, and 58th arginine in a nucleocapsid N protein sequence of PEDV is used as a target; the polypeptide is named as R58A polypeptide, and the amino acid sequence of the polypeptide is shown as SEQ ID NO: 1. According to the present invention, the key site affecting virus replication in the N-terminal region of the PEDV N protein is adopted as the new target, such that the inhibition effect in the PEDV infection model verification experiment of IPEC-J2, Vero and ST cells is significant, and the new target can be further adopted as the active component to prepare the porcine epidemic diarrhea resistance drug.

Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.

The invention relates to the technical field of molecular biology, in particular to a multichannel virus reporting system based on TAT trans-activation. The invention relates to a multichannel virus reporting system based on TAT trans-activation. The multichannel virus reporting system comprises an activated virus and a reporting cell, the activated virus is a human enterovirus A71 for expressing TAT protein; the reporter cells are cells transfected with reporter plasmids; the reporter plasmid comprises an LTR sequence and a plurality of reporter genes which are started to express by the LTR sequence. When the virus is activated to infect the reporter cell, the TAT protein carried by the virus enters the reporter cell to activate the expression of the downstream reporter gene, and the expression level of the reporter gene can reflect the virus replication condition, so that the screening or mechanism research of related antiviral drugs can be realized. According to the technical scheme, the technical problem that the flexibility, stability and high-throughput screening adaptability of a virus reporting system in the prior art are not ideal can be solved, and the virus reporting system has ideal popularization and application prospects.

Oncolytic viral vectors that incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle. Such viral vectors can be used for the treatment and prevention of cancer.

The present invention uses ex vivo human airway cultures to assess the human transmissibility and replication competence of influenza and coronavirus strains. By comparing pandemic influenza A subtype H1N1 and highly pathogenic avian influenza H5N1 as reference strains, the transmissibility risk of various viruses was evaluated and categorized. Additionally, an in vitro model evaluated virus-induced impairment of alveolar fluid clearance (AFC) as an indicator of disease severity. The study revealed correlations between bronchus viral replication, human transmission, AFC impairment, and clinical disease severity across different influenza and coronavirus strains.

The invention belongs to the technical field of gene engineering, and particularly relates to application of a TRIM3 gene or protein serving as a target spot in screening of drugs for inhibiting foot and mouth disease virus replication. The method specifically comprises the following steps: firstly, constructing a TRIM3 knockout cell line by utilizing a CRISPR / Cas9 system, wherein the cell line obviously inhibits the replication of FMDV; secondly, according to the invention, a TRIM3 stable expression cell line is constructed by using a lentivirus packaging system, and the cell line promotes the replication of FMDV. Therefore, the inhibition or silencing of the TRIM3 gene / protein can inhibit the replication of the foot-and-mouth disease virus, can be used as a target spot for screening drugs for inhibiting the replication of the foot-and-mouth disease virus, provides some theoretical bases for preventing or inhibiting FMDV infection in the future, and has a wide application prospect.

The present invention relates to a conjugate for inhibiting viral replication, a preparation method therefor, and use thereof. The conjugate comprises a dimer or trimer of a portion that inhibits influenza virus neuraminidase (e.g. zanamivir, peramivir, oseltamivir, or an analog thereof), the dimer or trimer being conjugated to an Fc domain monomer, an Fc domain, an Fc-binding peptide, an albumin, or an albumin-binding peptide. The conjugate can be used to treat viral infections (e.g., influenza virus infections).

The invention discloses a PDCoV JS2021-LX strain NS6 gene deletion recombinant virus and a construction method thereof, on the basis of PDCoV JS2021-LX strain infectious clone successfully constructed by a BAC system, the upstream and downstream of the NS6 gene are cut by adopting a CRISPR / Cas9 technology, then the original NS6 gene segment is replaced by green fluorescent protein EGFP through a homologous recombination mode, an NS6 gene deletion recombinant plasmid is obtained, and the NS6 gene deletion recombinant virus is constructed. And after the LLC-PK1 cell is transfected, the recombinant virus without the NS6 protein is rescued. The recombinant virus with the PDCoV NS6 gene deleted is successfully rescued, the virus replication level of the recombinant virus and the virus is rescued through in-vivo and in-vitro evaluation, and pig experiment results show that the pathogenicity of the recombinant virus is reduced, and the recombinant virus has the potential of serving as a candidate strain of an attenuated live vaccine.

To disclose modified influenza virus neuraminidases that improve viral replication, thus improving the yield of vaccine viruses.SOLUTION: Expression of such modified neuraminidases by influenza virus stabilizes co-expressed hemagglutinins, ensuring that the hemagglutinins do not undergo mutation or decrease the need for HA binding to cells.SELECTED DRAWING: None

The present invention relates to an alphavirus RNA replicase coding sequence, an optimized self-amplifying nucleic acid molecule, a pharmaceutical composition, and a use. The optimized self-amplifying nucleic acid molecule is a self-amplifying nucleic acid molecule comprising the alphavirus RNA replicase coding sequence, a tissue-specific self-amplifying nucleic acid molecule, or an improved self-amplifying mRNA comprising a mutated replicase; and the mutated replicase comprises a mutated macro domain. The present invention further relates to a preparation method for the self-amplifying nucleic acid molecule.

The invention relates to the technical field of biology, and aims to provide a zinc ion-containing influenza A virus culture medium and a preparation method thereof. The culture medium contains a serum-free cell culture medium, water, a PBS (Phosphate Buffer Solution), bovine serum albumin with the final concentration of 20g / L, TPCK-Trypsin with the final concentration of 2mu g / mL and zinc ions with the final concentration of 0.009-0.015 mmol / L. According to the invention, zinc ions which are originally considered to generate a virus inhibition effect under a relatively low concentration condition can be used for promoting virus replication after the use concentration range is adjusted; therefore, a brand-new culture medium which can be applied to research on common cell models and virus in-vitro culture models of the influenza A virus is provided, and a new solution is provided for optimizing a vaccine production process. The culture medium is simple in formula and convenient to prepare; all the raw material components are common consumables in laboratories, and the required liquid components can be prefabricated in advance and refrigerated for later use; and large-scale vaccine production can be supported.

The invention belongs to the technical field of medicines, and provides a compound for inhibiting virus replication and application of the compound in preparation of a medicine for resisting feline infectious peritonitis virus (FIPV). The number of the compounds provided by the invention is 10, and the 10 compounds have obvious inhibiting and blocking effects on a 1-bit ribosome frameshift process of the FIPV, and can effectively inhibit the replication and proliferation of the FIPV. The ten compounds can be used for treating and preventing feline infectious peritonitis diseases caused by FIPV infection; the compound disclosed by the invention can be used for preparing anti-FIPV medicines and medicines for treating and preventing feline infectious peritonitis diseases caused by FIPV infection, and has a wide application prospect.

The invention discloses application of a ZNF528 gene as a target spot in preparation of a medicine for inhibiting coronavirus replication, and belongs to the technical field of biological genetic engineering. In order to solve the technical problems of relatively low flexibility, low efficiency and relatively narrow applicability of a traditional host factor in the prior art, the invention provides application of a ZNF528 gene as a target spot in preparation of a medicine for inhibiting coronavirus replication, and a key gene ZNF528 which affects infection and invasion of coronavirus in a human host cell is screened by utilizing a CRISPR (clustered regularly interspaced short palindromic repeats) screening technology; the ZNF528 gene expression inhibitor provided by the invention can be applied to preparation of a coronavirus replication inhibitor; the ZNF528 gene expression synergist provided by the invention can be applied to preparation of a coronavirus replication synergist or a vaccine production synergist.

The invention provides a co-culture system of human alveolar epithelial cells and endothelial cells, which is used for researching interaction in an epithelial-endothelial barrier in lungs. It is indicated that infection with the highly pathogenic influenza A virus A / HK / 483 / 97 (H5N1) can significantly reduce alveolar fluid clearance (AFC) and increase protein permeability (APP). Administration of therapeutic extracellular vesicles (EV) after infection effectively restores AFC and APP, reduces viral replication, and enhances expression of antiviral genes. According to the invention, the treatment potential of EV is highlighted, and a valuable tool is provided for researching acute lung injury and improving a lung drug delivery technology.

The invention discloses a recombinant rabies virus genome plasmid for high-sensitivity expression of red fluorescent protein, a recombinant rabies virus as well as a preparation method and application of the recombinant rabies virus. The preparation method specifically comprises the following steps: (1) constructing the recombinant rabies virus genome plasmid for high-sensitivity expression of red fluorescent protein as shown in SEQ ID NO.2; (2) preparing a recombinant rabies virus for expressing the red fluorescent protein with high sensitivity; and (3) application of the recombinant rabies virus for high-sensitivity expression of the red fluorescent protein in neural circuit tracing. The recombinant rabies virus capable of highly sensitively expressing the red fluorescent protein can efficiently mark an upstream neural network in a retrograde manner, so that the problem of low efficiency of expressing red fluorescence in the existing method is solved; the method has wide application value and market prospect in the aspects of neural circuit structure and function analysis, neuron sparse marking, vaccine and drug research and development, disease model establishment, neural network loss and reconstruction detection, virus replication or pathogenic mechanism research and the like.

The invention belongs to the field of gene engineering, and particularly relates to application of an RSAD1 gene / protein serving as a target spot in screening of drugs for inhibiting picornaviridae virus infection. The silent RSAD1 gene is accidentally found to be capable of remarkably inhibiting the replication of the Seneca virus and can be used as a target spot for researching and developing an antiviral drug for the Seneca virus. The invention provides an sgRNA sequence of a targeted RSAD1 gene, a CRISPR-Cas9 gene editing technology is combined, the RSAD1 gene is silenced, an RSAD1 gene knockout monoclonal cell line is obtained, the cell line can remarkably inhibit the replication of Seneca virus, and a target spot is provided for further screening drugs and reagents for resisting the replication of Seneca virus; meanwhile, it is found that overexpression of the RSAD1 protein in host cells can significantly promote replication of Seneca viruses, and the RSAD1 protein can be used as a production cell line of Seneca viruses or vaccines and used for production of Seneca viruses or vaccines.

The invention belongs to the technical field of biological pharmacy, and particularly relates to an anti-coronavirus medicine and application. According to the application disclosed by the embodiment of the invention, experiments prove that the punicalagin and the punicalagin respectively have strong binding force to SARS-CoV-2 main protease Mpro and have a remarkable inhibition effect on SARS-CoV-2 virus replication, so that the punicalagin and the punicalagin can be used as novel SARS-CoV-2 inhibitors. Therefore, punicalagin and / or punicalagin can be used for preparing products for inhibiting novel coronavirus.

The invention discloses an application of a BAG6 gene in regulation of influenza virus replication. The invention provides any one of the following applications of the substance for inhibiting expression of the BAG6 gene or the encoded protein thereof: 1) preparing a product for expanding propagation of influenza virus; 2) preparing a product for promoting influenza virus replication; and 3) preparing a product for improving the expression quantity of the influenza virus related protein. Experiments prove that the function of the BAG6 gene encoding protein is lost, and the BAG6 gene encoding protein can be used for researching the cell biological function of the BAG6 protein and the action and mechanism in other viruses; in addition, the strain has the potential of being applied to influenza vaccine production. Besides, overexpression is carried out on the BAG6 protein, it is found that the BAG6 protein can inhibit the replication titer of the influenza virus and the expression of the protein, and the effect of the BAG6 protein in influenza virus replication is explored from the two aspects of knockout and overexpression.

The invention provides application of an IFI16 gene overexpression biological material in preparation of an anti-dengue virus drug, and belongs to the technical field of anti-dengue virus. According to the invention, differentially expressed genes after host cells transfect viruses are found, and the differentially expressed genes are analyzed, so that the key genes related to dengue virus resistance are determined; it is determined that the over-expressed IFI16 gene has the effect of inhibiting dengue virus replication and can be used for preparing the anti-dengue virus medicine.

This article provides a combination of compounds that can inhibit influenza virus replication, reduce influenza virus load, and / or treat influenza.

The invention belongs to the technical field of medicines, and discloses application of a compound in prevention and treatment of coronavirus infection and / or diseases caused by coronavirus. In particular discloses application of one or more of G96-69, G96-70, G102-35, G110-74, G115-49 and G118-1 in prevention and treatment of coronavirus infection and diseases caused by the coronavirus, improvement of symptoms caused by the coronavirus and in-vitro inhibition of coronavirus replication in a non-treatment destination, and the G96-69, the G96-70, the G102-35, the G110-74, the G115-49 and the G118-1 have relatively good effects in the aspect of resisting the coronavirus. EC50 for inhibiting mouse hepatitis virus MHV is less than 6 [mu] M; the EC 50 of the HCoV-OC43, the EC 50 of the HCoV-229E and the EC 50 of the HCoV-NL63 which are inhibited by the G96-69 and the G96-70 are all smaller than 2 [mu] M.

The present invention provides compounds that are 3CL protease inhibitors and their use in the treatment / or prophylaxis of viral infections, such as coronavirus infections. Experiments prove that the compounds have a relatively strong inhibition effect on 3CL protease, and can block virus replication by inhibiting the activity of the virus main protease 3CL so as to achieve an antiviral treatment effect. The compound has a novel structure prospect for treating and / or preventing coronavirus infection.

The invention provides the use of a formulation containing cyclodextrine, quercetin and zinc, at appropriate concentrations to mitigate infections by enveloped viruses like SARS-COV-2, influenza and HIV / AIDS, when administered via pulmonary and dermal route. While the different forms of cyclodextrin prevent the entry of coated virus into host cells by extracting and sequestering cholesterol molecules at the virus coat and at the host cell plasma membrane, the natural plant-based ionophore quercetin in the formulation, enables cellular entry of zinc, inhibiting viral replication by altering polymerase activity in the host cell. Hence cyclodextrine, and quercetin plus zinc, either in combination or in tandem order of administration, serves both as prophylactic and therapeutic.

This invention generally relates to a novel RNA / mRNA production and amplification method using viral RNA replicase and / or RNA-dependent RNA polymerase (RdRp) enzymes as well as the associated mRNAs thereof. The present invention can be used for manufacturing and amplifying all varieties of RNA / mRNA sequences carrying at least an RdRp-binding site in the 5′- or 3′-end, or both. The RNA / mRNA so obtained is useful for not only producing mRNA vaccines and / or RNA-based medicines but also for generating the mRNA-associated proteins, peptides, and / or antibodies under an in-vitro as well as in-cell translation condition. Principally, the present invention is a novel RNA replicase-mediated RNA / mRNA amplification method, namely Replicase Cycling Reaction (RCR). The RNA replicases involved in RCR include but not limited to viral and / or bacteriophage RNA-dependent RNA polymerases (RdRp), particularly coronaviral and hepatitis C viral (HCV) RdRp enzymes.

The present invention pertains to the use of a vaccine based on an alphavirus RNA replicon particle (αRP) vector encoding an antigen of an IAV-S for the passive vaccination of piglets against a pathogenic infection with swine influenza virus.

The invention belongs to the technical field of agricultural biology, and particularly relates to application of 4 mu 8C in preparation of a medicine for preventing and treating bombyx mori nuclear polyhedrosis virus. Bioinformatics analysis, gene knockout, RT-PCR detection and other modes find that BmIRE1alpha is used as an important molecular target for regulating and controlling bombyx mori nuclear polyhedrosis virus (BmNPV) replication, an inhibitor 4mu8C not only blocks virus replication, but also regulates and controls a bombyx mori endoplasmic reticulum stress pathway and the expression level of key genes, and the BmIRE1alpha can be used for regulating and controlling bombyx mori nuclear polyhedrosis virus (BmNPV) replication. And the cell stress burden caused by virus infection is relieved. Researches show that 4 mu 8C has an accurate and efficient antiviral effect, has more potential compared with traditional pesticides, avoids damage to the environment and non-target organisms, provides new technical support for green and sustainable development of sericulture, and has great development and application prospects.

To provide a method for propagating a recombinant influenza B virus, and a host cell.SOLUTION: A method for propagating a recombinant influenza B virus comprising a mutant BM2 gene having a specific sequence comprises: contacting a host cell with the recombinant influenza B virus; and incubating the host cell for a sufficient time and under conditions suitable for viral replication; where the host cell is an MDCK cell or a Vero cell expressing functional BM2 or chimeric M2-BM2 proteins.SELECTED DRAWING: None